Mobia Medical, Inc. Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MOBI research report →
Range $20 – $31
Price Chart
About the company
Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, including implantable systems for stroke rehabilitation and other neurological conditions. The company provides neurostimulation systems and devices that combine vagus nerve stimulation with therapy to address chronic neurological conditions.
- CEO
- Richard Foust
- IPO
- 2026
- Employees
- 167
- HQ
- Austin, TX, US
Get TickerSpark's AI analysis on MOBI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $394.50M
- P/E
- -5.64
- PEG
- 0.10
- P/S
- 7.60
- P/B
- 2.50
- EV/EBITDA
- -3.68
- Div Yield
- 0.00%
- Gross Margin
- 82.56%
- Op Margin
- -130.55%
- Net Margin
- -135.02%
- ROE
- -2335.92%
- ROIC
- -40.71%
Latest fiscal year · YoY change
- Revenue
- $32.04M+104.8%
- Gross Profit
- $25.98M+108.6%
- Op Income
- $-46,367,901
- Net Income
- $-46,498,188-89.0%
- EPS
- $-1.41-90.5%
- OCF Growth
- -87.9%
- FCF Growth
- -89.1%
- 52W High
- $15.29
- 52W Low
- $8.03
- 50D MA
- $10.31
- 200D MA
- $11.50
- Beta
- -0.54
- RSI (14)
- 53
- Avg Volume
- 214.96K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Mobia Medical posted 73% revenue growth in Q3, expanded active territories, and raised full-year guidance as Vivistim adoption and reimbursement momentum strengthened.· November 5, 2026
- Q3 revenue was $15.6 million, up 73% year over year, driven mainly by growth in existing programs and broader Vivistim adoption.
- Gross margin improved to 83.2% from 79.6%, helped by lower freight/tariff costs and fewer inventory write-offs.
- The company raised full-year 2026 revenue guidance to $57.0 million-$57.5 million from $54 million-$56 million.
- Active territories grew to 40 on average, up 78% from 22.5 a year ago, and management said new territory adds should continue at a consistent pace.
- Management highlighted the AHA/ASA guideline inclusion and the new APC code as important reimbursement and adoption tailwinds.
Q3 2026 revenue was $15.6 million, up 73% from $9 million in Q3 2025. The company sold approximately 425 units in the quarter. Gross margin was 83.2%, compared with 79.6% a year ago. Operating expenses were $31.5 million versus $18.4 million in Q3 2025, and net loss was $17.3 million, or $0.52 per share, versus $11.4 million, or $13.31 per share, in Q3 2025. Cash and cash equivalents were $160.7 million as of September 30, 2026. For full-year 2026, management raised revenue guidance to $57.0 million-$57.5 million from $54 million-$56 million, implying approximately 78%-79% growth over full-year 2025.
Richard Foust framed the quarter as proof that Mobia is building a new market in chronic stroke recovery, emphasizing strong patient demand, physician support, and the company’s first-of-its-kind FDA-approved device. He repeatedly pointed to the AHA/ASA guideline update, real-world clinical evidence, and reimbursement progress as validation points that should deepen hospital and physician adoption. His tone was confident and mission-driven, with a focus on long-term market build rather than near-term market share commentary.
Bunker Curnes focused on the financial drivers behind the beat and raise: revenue of $15.6 million, 73% growth, about 425 units sold, and gross margin of 83.2%. He said margin improved due to lower freight and tariff costs and lower inventory write-offs, and he expects gross margin to remain in the low 80s. He also noted operating expenses rose to $31.5 million mainly from headcount in the commercial organization and $2.2 million of stock-based compensation, while cash and cash equivalents ended at $160.7 million. On capital allocation, management said most spending is going toward commercial hiring, territory buildout, prior auth, and patient education.
Analysts pressed on whether the guidance raise simply reflected the Q3 beat and whether utilization assumptions changed; management said the quarter was driven by strong execution, especially in existing customers, and that it felt confident in the 78%-79% growth outlook. Questions also centered on reimbursement, including the new tech APC code; Richard Foust said the final rule supports the company’s current strategy and reinforced confidence in reimbursement next year. On commercial scaling, management said territory additions remain measured and consistent, with productivity still early and more growth currently coming from existing programs than from a mature installed base.
The call showed accelerating adoption, with revenue up 73%, gross margin above 80%, and management saying more growth came from existing customers. Supportive clinical and reimbursement catalysts — especially the AHA/ASA guideline inclusion and the new APC code — could help drive broader physician and hospital uptake.
The business is still early in its buildout, and management repeatedly said it is not yet ready to quantify territory maturity or long-term unit productivity. Operating expenses rose sharply to $31.5 million as the company continues to invest heavily in commercial expansion, and management said payer coverage expansion still depends on more data and more paid claims.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 6.2%
- Shares Outstanding
- 33.29M
- Float Shares
- 2.06M
of shares held by institutions
44 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Sr One Capital Management, LP | 1.99M | ▲ 1.99M |
| Farallon Capital Management, L.L.C. | 1.13M | ▲ 1.13M |
| Aberdeen Group PLC | 894.40K | ▲ 309.83K |
| Avidity Partners Management LP | 798.28K | ▲ 798.28K |
| Deerfield Management Company, L.P. | 670.75K | ▲ 670.75K |
| Blackrock, Inc. | 591.75K | ▲ 438.92K |
| Perceptive Advisors LLC | 523.65K | ▲ 523.65K |
| Vanguard Capital Management LLC | 444.36K | 0 |
| Rock Springs Capital Management LP | 418.20K | ▲ 418.20K |
| Balyasny Asset Management L.P. | 387.50K | ▲ 387.50K |
| Geode Capital Management, LLC | 256.70K | ▲ 131.12K |
| Integral Health Asset Management, LLC | 250.00K | ▲ 250.00K |
Held by 82 ETFs
Biggest fund positions in MOBI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 11, 26 | Leavitt Chase C. | buy | 2,000 |
| Sep 2, 26 | Rawat Prashant B. | other | 15,000 |
| Sep 2, 26 | Rawat Prashant B. | other | 15,000 |
| Aug 18, 26 | Tansey Casey M | buy | 16,441 |
| Aug 17, 26 | Tansey Casey M | buy | 17,166 |
| Aug 14, 26 | Tansey Casey M | buy | 100 |
| Aug 14, 26 | Tansey Casey M | buy | 15,721 |
| Aug 13, 26 | Tansey Casey M | buy | 35,572 |
| Jul 30, 26 | Curet Myriam | other | 19,740 |
| Jul 30, 26 | Curet Myriam | other | 15,960 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MOBI coverage
Recent articles, reports, and earnings notes.
No research on MOBI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MOBI report →Mobia Medical to Participate in the Piper Sandler 38th Annual Healthcare Conference
globenewswire.com · Nov 17
Mobia Medical, Inc. (MOBI) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 6
What Mobia Medical (MOBI) Said on Its Q3 Earnings Call
defenseworld.net · Nov 6
What Mobia Medical (MOBI) Said on Its Q3 Earnings Call
marketbeat.com · Nov 6
Mobia Medical Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 5
Mobia Medical to Participate in the 8th Annual Wolfe Research Healthcare Conference
globenewswire.com · Nov 3
Mobia Medical to Report Third Quarter 2026 Financial Results on November 5, 2026
globenewswire.com · Oct 15
Mobia Medical, Inc. (NASDAQ:MOBI) Stock Now Rated “Moderate Buy” by Sell-Side Analysts
defenseworld.net · Oct 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.